Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 10/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | PIK3R1 | P27986 | 4/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.33 |
| ▸ | WNT3A | P56704 | 1/20 | 0.32 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.32 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12675577 | 0.90 | PIK3CA (0.46) | PIK3CACYP3A4CHRM4PIK3R1KIT | |
| SCHEMBL2599992 | 0.84 | CYP3A4 (0.54) | PIK3CACYP3A4CHRM4KITALDH1A1 | |
| SCHEMBL12640333 | 0.83 | CYP3A4 (0.46) | PIK3CACYP3A4CHRM4PIK3R1WNT3A | |
| SCHEMBL12640366 | 0.81 | CYP3A4 (0.44) | PIK3CACYP3A4KITALDH1A1GAA | |
| SCHEMBL2599924 | 0.78 | CYP3A4 (0.45) | PIK3CACYP3A4ALDH1A1PIK3CDPIK3CB | |
| SCHEMBL12640370 | 0.78 | PDPK1 (0.37) | CYP3A4ALDH1A1 | |
| SCHEMBL30268699 | 0.77 | PIK3CA (0.49) | PIK3CAALDH1A1GAA | |
| SCHEMBL1892305 | 0.77 | PIK3CA (0.49) | PIK3CAALDH1A1GAA | |
| SCHEMBL12675576 | 0.75 | CYP3A4 (0.45) | PIK3CACYP3A4CHRM4PIK3R1KIT | |
| SCHEMBL12675345 | 0.74 | CYP3A4 (0.42) | PIK3CACYP3A4CHRM4KITPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096593-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096593-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140045840-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140045840-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2014-02-13 | — | — | US | disclosed |
| WO-2011057022-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20110112127-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112127-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | KIT, FLT3, BRAF | PIK3CA 308/4885CYP3A4 3717/4885CHRM4 4358/4885 |
| US-20140045840-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | KIT, FLT3, BRAF | PIK3CA 308/4885CYP3A4 3717/4885CHRM4 4358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.